TNFRSF1A and autoimmune disease: Conversely, therapeutic exploitation of the TNF–TNFR axis has led to effective drugs such as adalimumab and etanercept for autoimmune diseases as well as promising antitumor agents targeting the costimulatory immune receptors1,2.